Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma.

Cooper ZA, Reuben A, Spencer CN, Prieto PA, Austin-Breneman JL, Jiang H, Haymaker C, Gopalakrishnan V, Tetzlaff MT, Frederick DT, Sullivan RJ, Amaria RN, Patel SP, Hwu P, Woodman SE, Glitza IC, Diab A, Vence LM, Rodriguez-Canales J, Parra ER, Wistuba II, Coussens LM, Sharpe AH, Flaherty KT, Gershenwald JE, Chin L, Davies MA, Clise-Dwyer K, Allison JP, Sharma P, Wargo JA.

Oncoimmunology. 2016 Feb 2;5(3):e1136044. eCollection 2016 Mar.

2.

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.

Mahoney KM, Freeman GJ, McDermott DF.

Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29. Review.

3.

Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade.

Cooper ZA, Juneja VR, Sage PT, Frederick DT, Piris A, Mitra D, Lo JA, Hodi FS, Freeman GJ, Bosenberg MW, McMahon M, Flaherty KT, Fisher DE, Sharpe AH, Wargo JA.

Cancer Immunol Res. 2014 Jul;2(7):643-54. doi: 10.1158/2326-6066.CIR-13-0215. Epub 2014 Apr 29.

4.

Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma.

Deken MA, Gadiot J, Jordanova ES, Lacroix R, van Gool M, Kroon P, Pineda C, Geukes Foppen MH, Scolyer R, Song JY, Verbrugge I, Hoeller C, Dummer R, Haanen JB, Long GV, Blank CU.

Oncoimmunology. 2016 Oct 14;5(12):e1238557. doi: 10.1080/2162402X.2016.1238557. eCollection 2016.

5.

CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.

Ott PA, Hodi FS, Robert C.

Clin Cancer Res. 2013 Oct 1;19(19):5300-9. doi: 10.1158/1078-0432.CCR-13-0143. Review.

6.

Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade.

Wei SC, Levine JH, Cogdill AP, Zhao Y, Anang NAS, Andrews MC, Sharma P, Wang J, Wargo JA, Pe'er D, Allison JP.

Cell. 2017 Sep 7;170(6):1120-1133.e17. doi: 10.1016/j.cell.2017.07.024. Epub 2017 Aug 10.

7.

Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma.

Hermel DJ, Ott PA.

Cancer Metastasis Rev. 2017 Mar;36(1):43-50. doi: 10.1007/s10555-017-9656-2. Review. Erratum in: Cancer Metastasis Rev. 2017 Mar;36(1):51.

PMID:
28181070
8.

Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.

Ascierto PA, Agarwala S, Botti G, Cesano A, Ciliberto G, Davies MA, Demaria S, Dummer R, Eggermont AM, Ferrone S, Fu YX, Gajewski TF, Garbe C, Huber V, Khleif S, Krauthammer M, Lo RS, Masucci G, Palmieri G, Postow M, Puzanov I, Silk A, Spranger S, Stroncek DF, Tarhini A, Taube JM, Testori A, Wang E, Wargo JA, Yee C, Zarour H, Zitvogel L, Fox BA, Mozzillo N, Marincola FM, Thurin M.

J Transl Med. 2016 Nov 15;14(1):313.

9.

Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma.

Cooper ZA, Reuben A, Amaria RN, Wargo JA.

Oncoimmunology. 2014 Dec 13;3(9):e954956. eCollection 2014 Oct.

10.

Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma.

Kim T, Amaria RN, Spencer C, Reuben A, Cooper ZA, Wargo JA.

Cancer Biol Med. 2014 Dec;11(4):237-46. doi: 10.7497/j.issn.2095-3941.2014.04.002. Review.

11.

Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.

Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, De Macedo MP, Austin-Breneman JL, Jiang H, Chang Q, Reddy SM, Chen WS, Tetzlaff MT, Broaddus RJ, Davies MA, Gershenwald JE, Haydu L, Lazar AJ, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, Woodman SE, Vence LM, Wistuba II, Amaria RN, Kwong LN, Prieto V, Davis RE, Ma W, Overwijk WW, Sharpe AH, Hu J, Futreal PA, Blando J, Sharma P, Allison JP, Chin L, Wargo JA.

Cancer Discov. 2016 Aug;6(8):827-37. doi: 10.1158/2159-8290.CD-15-1545. Epub 2016 Jun 14.

12.

Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists.

Kakavand H, Wilmott JS, Long GV, Scolyer RA.

Pathology. 2016 Feb;48(2):194-202. doi: 10.1016/j.pathol.2015.12.010. Epub 2016 Jan 20. Review.

PMID:
27020392
13.

Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy.

Ma W, Gilligan BM, Yuan J, Li T.

J Hematol Oncol. 2016 May 27;9(1):47. doi: 10.1186/s13045-016-0277-y. Review.

14.

Cytotoxic T-lymphocyte antigen-4 blockade in melanoma.

Buchbinder EI, McDermott DF.

Clin Ther. 2015 Apr 1;37(4):755-63. doi: 10.1016/j.clinthera.2015.02.003. Epub 2015 Mar 6. Review.

PMID:
25746738
15.

Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?

Kelley MC.

Crit Rev Oncog. 2016;21(1-2):83-91. doi: 10.1615/CritRevOncog.2016017150. Review.

PMID:
27481005
16.

Immune Checkpoint Inhibitors in the Treatment of Melanoma: From Basic Science to Clinical Application.

Rausch MP, Hastings KT.

In: Ward WH, Farma JM, editors. Cutaneous Melanoma: Etiology and Therapy [Internet]. Brisbane (AU): Codon Publications; 2017 Dec 21. Chapter 9.

17.

Anti-PD-1/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8+ T cell trafficking.

Taggart D, Andreou T, Scott KJ, Williams J, Rippaus N, Brownlie RJ, Ilett EJ, Salmond RJ, Melcher A, Lorger M.

Proc Natl Acad Sci U S A. 2018 Feb 13;115(7):E1540-E1549. doi: 10.1073/pnas.1714089115. Epub 2018 Jan 31.

18.

[Recent Development of Therapies for Melanoma Using Immune Checkpoint Blockades].

Okuyama R.

Gan To Kagaku Ryoho. 2016 Jun;43(6):661-5. Japanese.

PMID:
27306802
19.

Immune Checkpoint Blockade in Breast Cancer Therapy.

Bu X, Yao Y, Li X.

Adv Exp Med Biol. 2017;1026:383-402. doi: 10.1007/978-981-10-6020-5_18. Review.

PMID:
29282694
20.

Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma.

Kähler KC, Hassel JC, Heinzerling L, Loquai C, Mössner R, Ugurel S, Zimmer L, Gutzmer R; “Cutaneous Side Effects” Committee of the Work Group Dermatological Oncology (ADO).

J Dtsch Dermatol Ges. 2016 Jul;14(7):662-81. doi: 10.1111/ddg.13047.

PMID:
27373241

Supplemental Content

Support Center